Lausanne, Switzerland-based AC Immune SA has filed to sell 6,000 shares in its initial public offering, priced between $11 and $13 a share, or about $63 million, the company said in a filing late Wednesday. The biotech company is developing therapies targeting Alzheimer's disease and others. The company is expected to trade on the NASDAQ under the symbol ACIU.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
